T cells designed to attack a blood cancer called hairy cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18 or older) with hairy cell leukemia (HCL) or a close variant (HCL-v), confirmed by a pathology review.
- Have signs you need treatment right now—such as low blood counts, an enlarged/symptomatic spleen, cancer growth, or certain cancer locations (including some spread to the CNS/brain area).
- Have enough cancer cells that can be targeted: CD22 must be present on more than 80% of the malignant (cancer) cells.
- Have measurable or detectable disease at enrollment, which may include very small amounts found on specialized tests (like MRD using flow cytometry or immunohistochemistry).
- Have acceptable body-organ health for treatment (for example: liver, kidney, and clotting tests within allowed ranges) and be recovered enough from prior therapy side effects.
- Have not received certain recent treatments (like chemotherapy/immunotherapy/radiation within 2 weeks of apheresis) and have no recent CAR T therapy showing lasting CAR T cells in the blood.
- Use reliable birth control if you can become pregnant or if you are a man able to father a child, and agree to stop breastfeeding during the study treatment window.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the best way to treat hairy cell leukemia and checks how well the approach works in people who need treatment for their disease. It may help if you have classic hairy cell leukemia and have not had certain prior chemotherapy.
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
Hear when a new Hairy Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.